Back to dashboard
All PlansCoverageMedium impact

Upcoming Policies effective December 1, 2025

Blue Cross and Blue Shield of Minnesota·MN · Cardiology, Cardiothoracic Surgery, Hematology +1 more·Medical Policy
Effective date
Dec 1, 2025
We identified it
Jun 20, 2026
Days to comply

Summary

Blue Cross MN has updated three medical policies effective December 1, 2025: transcatheter tricuspid valve procedures are now considered experimental/investigative, revised general medical necessity criteria for technologies without specific policies, and updated coverage criteria for hematopoietic stem cell transplantation in acute lymphoblastic leukemia patients.

Action Required

Action needed
By December 1, 2025: Review and update prior authorization processes for transcatheter tricuspid valve procedures (now experimental/investigative) and hematopoietic stem cell transplantation claims. Clinical team must ensure all medical necessity documentation meets the revised criteria outlined in policy XI-02. Update encounter forms and billing system notes to reflect new experimental status for tricuspid valve procedures and updated ALL treatment criteria.